Aquilo Capital Management LLC 13D and 13G filings for Spero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 11:16 am Sale |
2022-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 0 0.000% |
-3,419,435 (Position Closed) |
Filing |
| 2022-10-03 4:40 pm Sale |
2022-09-22 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 3,419,435 9.800% |
-1,602,101 (-31.90%) |
Filing |
| 2022-03-08 5:41 pm Purchase |
2022-01-18 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 5,021,536 15.500% |
57,355 (+1.16%) |
Filing |
| 2022-02-14 3:54 pm Purchase |
2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 4,964,181 15.400% |
1,031,972 (+26.24%) |
Filing |
| 2021-02-16 4:00 pm Sale |
2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 3,932,209 14.500% |
-564,933 (-12.56%) |
Filing |
| 2020-09-22 6:51 pm Purchase |
2020-09-11 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 4,497,142 17.400% |
3,342,786 (+289.58%) |
Filing |